|

Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis

RECRUITINGSponsored by University Hospital, Essen
Actively Recruiting
SponsorUniversity Hospital, Essen
Started2019-12-09
Est. completion2025-10
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07154381

Summary

Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age \> 40 years
* proven Amyloidosis (ATTR or AL)
* Women: negative pregnancy test less than weeks prior imaging.

Exclusion Criteria:

* Patients receiving amyloidosis-specific treatment prior study inclusion.
* Patients participating in other clinical trails for treatment of Amyloidosis.
* Pregnancy
* Contraindiactions for MRI (eGFR\<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).
* inability of consent
* Refusal of consent

Conditions2

Cardiac AmyloidosisHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.